Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Contact
About us
Links
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
Market Strategy
Articles
News
Daily Comment
Visie Van De Week
Real-time charts
About us
Contact
Links
About us
Contact
Links
Accordion Title
Accordion Content
more items +
Stocks are stumbling after Labor Day. This year’s easy gains may be over.
Why a stronger Japanese currency could spell trouble for AI and technology stocks
Why you shouldn’t stake your entire retirement plan on getting an inheritance
A contrarian case for stock-market gains through the midterm election
Is IBM’s selloff an opportunity? Here’s one case for the beaten-down stock.
I did everything ‘right’ with my health insurance — and still got a surprise bill. Here’s what I learned.
These software stocks are in a prime spot to benefit from a rapidly shifting AI landscape
Bombardier’s stock drops as the U.S.-Canada trade war intensifies. Here’s what Trump may target next.
Intel’s stock is rising as the company looks primed to boost prices even more
Oracle’s stock gets a boost as the OpenAI ecosystem comes back into favor
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
Prenups aren’t just for the rich. Here’s what they can cover.
Stocks are stumbling after Labor Day. This year’s easy gains may be over.
Why a stronger Japanese currency could spell trouble for AI and technology stocks
Why you shouldn’t stake your entire retirement plan on getting an inheritance
A contrarian case for stock-market gains through the midterm election
Is IBM’s selloff an opportunity? Here’s one case for the beaten-down stock.
I did everything ‘right’ with my health insurance — and still got a surprise bill. Here’s what I learned.
These software stocks are in a prime spot to benefit from a rapidly shifting AI landscape
Bombardier’s stock drops as the U.S.-Canada trade war intensifies. Here’s what Trump may target next.
Intel’s stock is rising as the company looks primed to boost prices even more
Oracle’s stock gets a boost as the OpenAI ecosystem comes back into favor
Novartis’s failed trial for cholesterol drug leads to broad biopharma stock selloff
Prenups aren’t just for the rich. Here’s what they can cover.
A contrarian case for stock-market gains through the midterm election
8-09-26
Yet another lease on life for the bull market, observes Mark Hulbert.
Share this on:
